nodes	percent_of_prediction	percent_of_DWPC	metapath
Baclofen—GABBR2—Activation of G protein gated Potassium channels—GNG7—esophageal cancer	0.0318	0.0765	CbGpPWpGaD
Baclofen—GABBR2—Inwardly rectifying K+ channels—GNG7—esophageal cancer	0.0268	0.0644	CbGpPWpGaD
Baclofen—GABBR2—Activation of GABAB receptors—GNG7—esophageal cancer	0.0228	0.0547	CbGpPWpGaD
Baclofen—GABBR1—Activation of G protein gated Potassium channels—GNG7—esophageal cancer	0.0205	0.0493	CbGpPWpGaD
Baclofen—GABBR2—GABA receptor activation—GNG7—esophageal cancer	0.0175	0.0419	CbGpPWpGaD
Baclofen—GABBR1—Inwardly rectifying K+ channels—GNG7—esophageal cancer	0.0173	0.0415	CbGpPWpGaD
Baclofen—GABBR1—Activation of GABAB receptors—GNG7—esophageal cancer	0.0147	0.0353	CbGpPWpGaD
Baclofen—GABBR1—GABA receptor activation—GNG7—esophageal cancer	0.0112	0.027	CbGpPWpGaD
Baclofen—GABBR2—Potassium Channels—GNG7—esophageal cancer	0.0106	0.0254	CbGpPWpGaD
Baclofen—Chlorphenesin—CYP19A1—esophageal cancer	0.00806	0.251	CrCbGaD
Baclofen—GABBR2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNG7—esophageal cancer	0.00802	0.0193	CbGpPWpGaD
Baclofen—Ibuprofen—BCL2—esophageal cancer	0.00708	0.22	CrCbGaD
Baclofen—GABBR1—Potassium Channels—GNG7—esophageal cancer	0.00682	0.0164	CbGpPWpGaD
Baclofen—GABBR2—Transmission across Chemical Synapses—GNG7—esophageal cancer	0.00603	0.0145	CbGpPWpGaD
Baclofen—GABBR2—GPCR ligand binding—ADCYAP1—esophageal cancer	0.00573	0.0138	CbGpPWpGaD
Baclofen—GABBR2—Transmission across Chemical Synapses—ALDH2—esophageal cancer	0.00565	0.0136	CbGpPWpGaD
Baclofen—GABBR2—G alpha (i) signalling events—GNG7—esophageal cancer	0.0053	0.0127	CbGpPWpGaD
Baclofen—GABBR1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—GNG7—esophageal cancer	0.00517	0.0124	CbGpPWpGaD
Baclofen—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC39A6—esophageal cancer	0.00506	0.0122	CbGpPWpGaD
Baclofen—Chlorpropamide—PTGS1—esophageal cancer	0.00492	0.153	CrCbGaD
Baclofen—GABBR2—G alpha (i) signalling events—CXCL2—esophageal cancer	0.00467	0.0112	CbGpPWpGaD
Baclofen—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC30A7—esophageal cancer	0.00463	0.0111	CbGpPWpGaD
Baclofen—GABBR2—Neuronal System—GNG7—esophageal cancer	0.00462	0.0111	CbGpPWpGaD
Baclofen—GABBR2—G alpha (i) signalling events—ANXA1—esophageal cancer	0.00434	0.0104	CbGpPWpGaD
Baclofen—GABBR2—Neuronal System—ALDH2—esophageal cancer	0.00433	0.0104	CbGpPWpGaD
Baclofen—GABBR2—G alpha (i) signalling events—SST—esophageal cancer	0.00422	0.0102	CbGpPWpGaD
Baclofen—GABBR1—Transmission across Chemical Synapses—GNG7—esophageal cancer	0.00389	0.00934	CbGpPWpGaD
Baclofen—Chlorphenesin—PTGS2—esophageal cancer	0.00371	0.115	CrCbGaD
Baclofen—GABBR1—GPCR ligand binding—ADCYAP1—esophageal cancer	0.00369	0.00887	CbGpPWpGaD
Baclofen—GABBR1—Transmission across Chemical Synapses—ALDH2—esophageal cancer	0.00364	0.00875	CbGpPWpGaD
Baclofen—GABBR1—G alpha (i) signalling events—GNG7—esophageal cancer	0.00342	0.00821	CbGpPWpGaD
Baclofen—GABBR2—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.00324	0.00778	CbGpPWpGaD
Baclofen—GABBR2—GPCR ligand binding—GNG7—esophageal cancer	0.00321	0.00772	CbGpPWpGaD
Baclofen—Pulmonary embolism—Capecitabine—esophageal cancer	0.00306	0.00555	CcSEcCtD
Baclofen—Gastrointestinal haemorrhage—Cisplatin—esophageal cancer	0.00302	0.00547	CcSEcCtD
Baclofen—GABBR1—G alpha (i) signalling events—CXCL2—esophageal cancer	0.00301	0.00723	CbGpPWpGaD
Baclofen—GABBR1—Neuronal System—GNG7—esophageal cancer	0.00298	0.00716	CbGpPWpGaD
Baclofen—Urinary incontinence—Capecitabine—esophageal cancer	0.00296	0.00536	CcSEcCtD
Baclofen—GABBR2—Signaling by GPCR—ADCYAP1—esophageal cancer	0.00294	0.00706	CbGpPWpGaD
Baclofen—Skin ulcer—Methotrexate—esophageal cancer	0.00293	0.00531	CcSEcCtD
Baclofen—Face oedema—Cisplatin—esophageal cancer	0.00291	0.00528	CcSEcCtD
Baclofen—Ibuprofen—PTGS1—esophageal cancer	0.0029	0.0902	CrCbGaD
Baclofen—GABBR2—GPCR ligand binding—CXCL2—esophageal cancer	0.00283	0.0068	CbGpPWpGaD
Baclofen—Dehydration—Cisplatin—esophageal cancer	0.00281	0.00508	CcSEcCtD
Baclofen—GABBR1—G alpha (i) signalling events—ANXA1—esophageal cancer	0.0028	0.00673	CbGpPWpGaD
Baclofen—GABBR1—Neuronal System—ALDH2—esophageal cancer	0.00279	0.00671	CbGpPWpGaD
Baclofen—Petechiae—Methotrexate—esophageal cancer	0.00277	0.00502	CcSEcCtD
Baclofen—Orthostatic hypotension—Cisplatin—esophageal cancer	0.00276	0.00499	CcSEcCtD
Baclofen—Breast disorder—Cisplatin—esophageal cancer	0.00273	0.00494	CcSEcCtD
Baclofen—GABBR1—G alpha (i) signalling events—SST—esophageal cancer	0.00272	0.00654	CbGpPWpGaD
Baclofen—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.00272	0.00492	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—GDI2—esophageal cancer	0.00269	0.00648	CbGpPWpGaD
Baclofen—Apnoea—Methotrexate—esophageal cancer	0.00269	0.00488	CcSEcCtD
Baclofen—Abnormal vision—Capecitabine—esophageal cancer	0.00267	0.00484	CcSEcCtD
Baclofen—Mental disability—Capecitabine—esophageal cancer	0.00266	0.00482	CcSEcCtD
Baclofen—Sepsis—Capecitabine—esophageal cancer	0.00266	0.00482	CcSEcCtD
Baclofen—Speech disorder—Methotrexate—esophageal cancer	0.00265	0.00481	CcSEcCtD
Baclofen—GABBR2—GPCR ligand binding—ANXA1—esophageal cancer	0.00263	0.00632	CbGpPWpGaD
Baclofen—Thrombophlebitis—Capecitabine—esophageal cancer	0.00257	0.00466	CcSEcCtD
Baclofen—GABBR2—GPCR ligand binding—SST—esophageal cancer	0.00256	0.00615	CbGpPWpGaD
Baclofen—Blood alkaline phosphatase increased—Capecitabine—esophageal cancer	0.00256	0.00463	CcSEcCtD
Baclofen—Hepatic function abnormal—Capecitabine—esophageal cancer	0.00254	0.00461	CcSEcCtD
Baclofen—Musculoskeletal stiffness—Methotrexate—esophageal cancer	0.00254	0.00461	CcSEcCtD
Baclofen—Sweating increased—Cisplatin—esophageal cancer	0.00254	0.0046	CcSEcCtD
Baclofen—Swelling—Capecitabine—esophageal cancer	0.00252	0.00457	CcSEcCtD
Baclofen—Gastroenteritis—Capecitabine—esophageal cancer	0.00251	0.00455	CcSEcCtD
Baclofen—GABBR2—GPCR ligand binding—GHRL—esophageal cancer	0.00249	0.00599	CbGpPWpGaD
Baclofen—Oliguria—Methotrexate—esophageal cancer	0.00247	0.00449	CcSEcCtD
Baclofen—Dysarthria—Methotrexate—esophageal cancer	0.00241	0.00437	CcSEcCtD
Baclofen—Chlorpropamide—ABCB1—esophageal cancer	0.00239	0.0744	CrCbGaD
Baclofen—Amnesia—Capecitabine—esophageal cancer	0.00237	0.00429	CcSEcCtD
Baclofen—Respiratory failure—Methotrexate—esophageal cancer	0.00232	0.00421	CcSEcCtD
Baclofen—SLC22A8—SLC-mediated transmembrane transport—SLC39A6—esophageal cancer	0.0023	0.00553	CbGpPWpGaD
Baclofen—Renal failure—Cisplatin—esophageal cancer	0.00229	0.00414	CcSEcCtD
Baclofen—Pulmonary embolism—Methotrexate—esophageal cancer	0.00228	0.00413	CcSEcCtD
Baclofen—Vaginal inflammation—Methotrexate—esophageal cancer	0.00228	0.00413	CcSEcCtD
Baclofen—Cerebrovascular accident—Capecitabine—esophageal cancer	0.00227	0.00411	CcSEcCtD
Baclofen—Lethargy—Capecitabine—esophageal cancer	0.00227	0.00411	CcSEcCtD
Baclofen—Osteoarthritis—Capecitabine—esophageal cancer	0.00222	0.00403	CcSEcCtD
Baclofen—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.00222	0.00403	CcSEcCtD
Baclofen—Diplopia—Capecitabine—esophageal cancer	0.00222	0.00403	CcSEcCtD
Baclofen—Hepatobiliary disease—Cisplatin—esophageal cancer	0.0022	0.00398	CcSEcCtD
Baclofen—Vaginal infection—Methotrexate—esophageal cancer	0.00215	0.0039	CcSEcCtD
Baclofen—Face oedema—Capecitabine—esophageal cancer	0.00215	0.00389	CcSEcCtD
Baclofen—Bradycardia—Cisplatin—esophageal cancer	0.00212	0.00385	CcSEcCtD
Baclofen—Urinary retention—Capecitabine—esophageal cancer	0.00211	0.00383	CcSEcCtD
Baclofen—Mood swings—Capecitabine—esophageal cancer	0.00211	0.00382	CcSEcCtD
Baclofen—SLC22A8—SLC-mediated transmembrane transport—SLC30A7—esophageal cancer	0.0021	0.00506	CbGpPWpGaD
Baclofen—Ataxia—Capecitabine—esophageal cancer	0.00209	0.00379	CcSEcCtD
Baclofen—GABBR1—GPCR downstream signaling—ADCYAP1—esophageal cancer	0.00209	0.00501	CbGpPWpGaD
Baclofen—GABBR2—GPCR downstream signaling—AKAP13—esophageal cancer	0.00209	0.00501	CbGpPWpGaD
Baclofen—Coma—Methotrexate—esophageal cancer	0.00208	0.00378	CcSEcCtD
Baclofen—GABBR1—GPCR ligand binding—GNG7—esophageal cancer	0.00207	0.00497	CbGpPWpGaD
Baclofen—Dehydration—Capecitabine—esophageal cancer	0.00207	0.00375	CcSEcCtD
Baclofen—Bladder pain—Methotrexate—esophageal cancer	0.00206	0.00374	CcSEcCtD
Baclofen—Urinary tract disorder—Cisplatin—esophageal cancer	0.00206	0.00374	CcSEcCtD
Baclofen—Connective tissue disorder—Cisplatin—esophageal cancer	0.00205	0.00372	CcSEcCtD
Baclofen—Urethral disorder—Cisplatin—esophageal cancer	0.00205	0.00371	CcSEcCtD
Baclofen—Orthostatic hypotension—Capecitabine—esophageal cancer	0.00203	0.00368	CcSEcCtD
Baclofen—Visual impairment—Cisplatin—esophageal cancer	0.00201	0.00365	CcSEcCtD
Baclofen—Breast disorder—Capecitabine—esophageal cancer	0.00201	0.00364	CcSEcCtD
Baclofen—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.002	0.00363	CcSEcCtD
Baclofen—Sepsis—Methotrexate—esophageal cancer	0.00198	0.00359	CcSEcCtD
Baclofen—Muscular weakness—Capecitabine—esophageal cancer	0.00196	0.00355	CcSEcCtD
Baclofen—Eye disorder—Cisplatin—esophageal cancer	0.00195	0.00353	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—KMT2D—esophageal cancer	0.00195	0.00468	CbGpPWpGaD
Baclofen—Tinnitus—Cisplatin—esophageal cancer	0.00195	0.00353	CcSEcCtD
Baclofen—Cardiac disorder—Cisplatin—esophageal cancer	0.00194	0.00351	CcSEcCtD
Baclofen—Flushing—Cisplatin—esophageal cancer	0.00194	0.00351	CcSEcCtD
Baclofen—Influenza—Capecitabine—esophageal cancer	0.00192	0.00348	CcSEcCtD
Baclofen—Dysphagia—Capecitabine—esophageal cancer	0.00192	0.00348	CcSEcCtD
Baclofen—Thrombophlebitis—Methotrexate—esophageal cancer	0.00191	0.00347	CcSEcCtD
Baclofen—GABBR2—GPCR downstream signaling—PDE4D—esophageal cancer	0.00191	0.00458	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—AKAP13—esophageal cancer	0.00189	0.00455	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—ADCYAP1—esophageal cancer	0.00189	0.00455	CbGpPWpGaD
Baclofen—Mediastinal disorder—Cisplatin—esophageal cancer	0.00188	0.00341	CcSEcCtD
Baclofen—Sweating increased—Capecitabine—esophageal cancer	0.00187	0.00339	CcSEcCtD
Baclofen—Arrhythmia—Cisplatin—esophageal cancer	0.00186	0.00338	CcSEcCtD
Baclofen—Alopecia—Cisplatin—esophageal cancer	0.00184	0.00334	CcSEcCtD
Baclofen—GABBR1—GPCR ligand binding—CXCL2—esophageal cancer	0.00182	0.00438	CbGpPWpGaD
Baclofen—Malnutrition—Cisplatin—esophageal cancer	0.00182	0.00329	CcSEcCtD
Baclofen—GABBR2—GPCR downstream signaling—GNG7—esophageal cancer	0.00181	0.00436	CbGpPWpGaD
Baclofen—Dysuria—Capecitabine—esophageal cancer	0.0018	0.00326	CcSEcCtD
Baclofen—Flatulence—Cisplatin—esophageal cancer	0.00179	0.00324	CcSEcCtD
Baclofen—Weight increased—Capecitabine—esophageal cancer	0.00175	0.00317	CcSEcCtD
Baclofen—Visual disturbance—Methotrexate—esophageal cancer	0.00175	0.00317	CcSEcCtD
Baclofen—Weight decreased—Capecitabine—esophageal cancer	0.00174	0.00315	CcSEcCtD
Baclofen—GABBR1—Signaling Pathways—GDI2—esophageal cancer	0.00174	0.00417	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—ADCYAP1—esophageal cancer	0.00174	0.00417	CbGpPWpGaD
Baclofen—Hyperglycaemia—Capecitabine—esophageal cancer	0.00173	0.00314	CcSEcCtD
Baclofen—GABBR2—Signaling by GPCR—PDE4D—esophageal cancer	0.00173	0.00416	CbGpPWpGaD
Baclofen—Pneumonia—Capecitabine—esophageal cancer	0.00172	0.00312	CcSEcCtD
Baclofen—Vision blurred—Cisplatin—esophageal cancer	0.00171	0.0031	CcSEcCtD
Baclofen—Depression—Capecitabine—esophageal cancer	0.00171	0.0031	CcSEcCtD
Baclofen—Tremor—Cisplatin—esophageal cancer	0.0017	0.00308	CcSEcCtD
Baclofen—GABBR1—GPCR ligand binding—ANXA1—esophageal cancer	0.00169	0.00407	CbGpPWpGaD
Baclofen—Cerebrovascular accident—Methotrexate—esophageal cancer	0.00169	0.00306	CcSEcCtD
Baclofen—Lethargy—Methotrexate—esophageal cancer	0.00169	0.00306	CcSEcCtD
Baclofen—Ill-defined disorder—Cisplatin—esophageal cancer	0.00169	0.00306	CcSEcCtD
Baclofen—Renal failure—Capecitabine—esophageal cancer	0.00168	0.00305	CcSEcCtD
Baclofen—Anaemia—Cisplatin—esophageal cancer	0.00168	0.00304	CcSEcCtD
Baclofen—Osteoarthritis—Methotrexate—esophageal cancer	0.00166	0.003	CcSEcCtD
Baclofen—Ibuprofen—PTGS2—esophageal cancer	0.00166	0.0515	CrCbGaD
Baclofen—GABBR1—GPCR ligand binding—SST—esophageal cancer	0.00165	0.00396	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—GNG7—esophageal cancer	0.00165	0.00396	CbGpPWpGaD
Baclofen—Malaise—Cisplatin—esophageal cancer	0.00164	0.00297	CcSEcCtD
Baclofen—Haematuria—Capecitabine—esophageal cancer	0.00163	0.00296	CcSEcCtD
Baclofen—Hepatobiliary disease—Capecitabine—esophageal cancer	0.00162	0.00294	CcSEcCtD
Baclofen—GABBR1—GPCR ligand binding—GHRL—esophageal cancer	0.00161	0.00386	CbGpPWpGaD
Baclofen—GABBR2—GPCR downstream signaling—CXCL2—esophageal cancer	0.0016	0.00384	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—WWOX—esophageal cancer	0.00159	0.00382	CbGpPWpGaD
Baclofen—Convulsion—Cisplatin—esophageal cancer	0.00157	0.00285	CcSEcCtD
Baclofen—Mood swings—Methotrexate—esophageal cancer	0.00157	0.00284	CcSEcCtD
Baclofen—Bradycardia—Capecitabine—esophageal cancer	0.00157	0.00284	CcSEcCtD
Baclofen—Ataxia—Methotrexate—esophageal cancer	0.00156	0.00282	CcSEcCtD
Baclofen—Myalgia—Cisplatin—esophageal cancer	0.00155	0.0028	CcSEcCtD
Baclofen—Rhinitis—Capecitabine—esophageal cancer	0.00154	0.0028	CcSEcCtD
Baclofen—Anxiety—Cisplatin—esophageal cancer	0.00154	0.00279	CcSEcCtD
Baclofen—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00154	0.00278	CcSEcCtD
Baclofen—Hypoaesthesia—Capecitabine—esophageal cancer	0.00153	0.00277	CcSEcCtD
Baclofen—Discomfort—Cisplatin—esophageal cancer	0.00153	0.00277	CcSEcCtD
Baclofen—Urinary tract disorder—Capecitabine—esophageal cancer	0.00152	0.00275	CcSEcCtD
Baclofen—Oedema peripheral—Capecitabine—esophageal cancer	0.00152	0.00275	CcSEcCtD
Baclofen—Connective tissue disorder—Capecitabine—esophageal cancer	0.00151	0.00274	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—FKBP1A—esophageal cancer	0.00151	0.00363	CbGpPWpGaD
Baclofen—Urethral disorder—Capecitabine—esophageal cancer	0.00151	0.00273	CcSEcCtD
Baclofen—Breast disorder—Methotrexate—esophageal cancer	0.0015	0.00271	CcSEcCtD
Baclofen—GABBR2—GPCR downstream signaling—ANXA1—esophageal cancer	0.00149	0.00357	CbGpPWpGaD
Baclofen—Oedema—Cisplatin—esophageal cancer	0.00148	0.00269	CcSEcCtD
Baclofen—Visual impairment—Capecitabine—esophageal cancer	0.00148	0.00269	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—WIF1—esophageal cancer	0.00148	0.00355	CbGpPWpGaD
Baclofen—Infection—Cisplatin—esophageal cancer	0.00147	0.00267	CcSEcCtD
Baclofen—Nervous system disorder—Cisplatin—esophageal cancer	0.00145	0.00264	CcSEcCtD
Baclofen—GABBR2—Signaling by GPCR—CXCL2—esophageal cancer	0.00145	0.00349	CbGpPWpGaD
Baclofen—Tachycardia—Cisplatin—esophageal cancer	0.00145	0.00262	CcSEcCtD
Baclofen—GABBR2—GPCR downstream signaling—SST—esophageal cancer	0.00145	0.00347	CbGpPWpGaD
Baclofen—Skin disorder—Cisplatin—esophageal cancer	0.00144	0.00261	CcSEcCtD
Baclofen—Eye disorder—Capecitabine—esophageal cancer	0.00144	0.00261	CcSEcCtD
Baclofen—Tinnitus—Capecitabine—esophageal cancer	0.00143	0.0026	CcSEcCtD
Baclofen—Hyperhidrosis—Cisplatin—esophageal cancer	0.00143	0.0026	CcSEcCtD
Baclofen—Flushing—Capecitabine—esophageal cancer	0.00143	0.00259	CcSEcCtD
Baclofen—Cardiac disorder—Capecitabine—esophageal cancer	0.00143	0.00259	CcSEcCtD
Baclofen—Anorexia—Cisplatin—esophageal cancer	0.00141	0.00256	CcSEcCtD
Baclofen—GABBR2—GPCR downstream signaling—GHRL—esophageal cancer	0.00141	0.00339	CbGpPWpGaD
Baclofen—Ibuprofen—ABCB1—esophageal cancer	0.00141	0.0438	CrCbGaD
Baclofen—Angiopathy—Capecitabine—esophageal cancer	0.0014	0.00253	CcSEcCtD
Baclofen—Mediastinal disorder—Capecitabine—esophageal cancer	0.00139	0.00251	CcSEcCtD
Baclofen—Hypotension—Cisplatin—esophageal cancer	0.00139	0.00251	CcSEcCtD
Baclofen—Chills—Capecitabine—esophageal cancer	0.00138	0.0025	CcSEcCtD
Baclofen—Arrhythmia—Capecitabine—esophageal cancer	0.00137	0.00249	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—CSNK1A1—esophageal cancer	0.00136	0.00327	CbGpPWpGaD
Baclofen—Alopecia—Capecitabine—esophageal cancer	0.00136	0.00246	CcSEcCtD
Baclofen—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00135	0.00245	CcSEcCtD
Baclofen—GABBR2—Signaling by GPCR—ANXA1—esophageal cancer	0.00135	0.00324	CbGpPWpGaD
Baclofen—Mental disorder—Capecitabine—esophageal cancer	0.00135	0.00244	CcSEcCtD
Baclofen—GABBR1—GPCR downstream signaling—AKAP13—esophageal cancer	0.00134	0.00323	CbGpPWpGaD
Baclofen—Malnutrition—Capecitabine—esophageal cancer	0.00134	0.00243	CcSEcCtD
Baclofen—Dysuria—Methotrexate—esophageal cancer	0.00134	0.00242	CcSEcCtD
Baclofen—Paraesthesia—Cisplatin—esophageal cancer	0.00133	0.00241	CcSEcCtD
Baclofen—Dyspnoea—Cisplatin—esophageal cancer	0.00132	0.0024	CcSEcCtD
Baclofen—Flatulence—Capecitabine—esophageal cancer	0.00132	0.00239	CcSEcCtD
Baclofen—Erectile dysfunction—Methotrexate—esophageal cancer	0.00132	0.00239	CcSEcCtD
Baclofen—GABBR2—Signaling by GPCR—SST—esophageal cancer	0.00131	0.00315	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.00131	0.00315	CbGpPWpGaD
Baclofen—Dysgeusia—Capecitabine—esophageal cancer	0.00131	0.00238	CcSEcCtD
Baclofen—Back pain—Capecitabine—esophageal cancer	0.0013	0.00235	CcSEcCtD
Baclofen—Decreased appetite—Cisplatin—esophageal cancer	0.00129	0.00234	CcSEcCtD
Baclofen—Pneumonia—Methotrexate—esophageal cancer	0.00128	0.00233	CcSEcCtD
Baclofen—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00128	0.00232	CcSEcCtD
Baclofen—GABBR2—Signaling by GPCR—GHRL—esophageal cancer	0.00128	0.00307	CbGpPWpGaD
Baclofen—Drowsiness—Methotrexate—esophageal cancer	0.00128	0.00231	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—PFN1—esophageal cancer	0.00127	0.00306	CbGpPWpGaD
Baclofen—Depression—Methotrexate—esophageal cancer	0.00127	0.00231	CcSEcCtD
Baclofen—Pain—Cisplatin—esophageal cancer	0.00127	0.0023	CcSEcCtD
Baclofen—Vision blurred—Capecitabine—esophageal cancer	0.00126	0.00229	CcSEcCtD
Baclofen—GABBR1—Signaling Pathways—KMT2D—esophageal cancer	0.00126	0.00302	CbGpPWpGaD
Baclofen—Tremor—Capecitabine—esophageal cancer	0.00125	0.00227	CcSEcCtD
Baclofen—Renal failure—Methotrexate—esophageal cancer	0.00125	0.00227	CcSEcCtD
Baclofen—Ill-defined disorder—Capecitabine—esophageal cancer	0.00124	0.00225	CcSEcCtD
Baclofen—Anaemia—Capecitabine—esophageal cancer	0.00124	0.00224	CcSEcCtD
Baclofen—SLC22A8—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.00123	0.00296	CbGpPWpGaD
Baclofen—GABBR1—GPCR downstream signaling—PDE4D—esophageal cancer	0.00123	0.00295	CbGpPWpGaD
Baclofen—Sweating—Methotrexate—esophageal cancer	0.00122	0.00222	CcSEcCtD
Baclofen—Feeling abnormal—Cisplatin—esophageal cancer	0.00122	0.00221	CcSEcCtD
Baclofen—GABBR1—Signaling by GPCR—AKAP13—esophageal cancer	0.00122	0.00293	CbGpPWpGaD
Baclofen—Haematuria—Methotrexate—esophageal cancer	0.00122	0.0022	CcSEcCtD
Baclofen—Malaise—Capecitabine—esophageal cancer	0.00121	0.00219	CcSEcCtD
Baclofen—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00121	0.00219	CcSEcCtD
Baclofen—Vertigo—Capecitabine—esophageal cancer	0.0012	0.00218	CcSEcCtD
Baclofen—Syncope—Capecitabine—esophageal cancer	0.0012	0.00218	CcSEcCtD
Baclofen—Palpitations—Capecitabine—esophageal cancer	0.00118	0.00214	CcSEcCtD
Baclofen—Loss of consciousness—Capecitabine—esophageal cancer	0.00118	0.00213	CcSEcCtD
Baclofen—Body temperature increased—Cisplatin—esophageal cancer	0.00117	0.00212	CcSEcCtD
Baclofen—GABBR1—GPCR downstream signaling—GNG7—esophageal cancer	0.00117	0.00281	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.00117	0.00281	CbGpPWpGaD
Baclofen—Hypertension—Capecitabine—esophageal cancer	0.00116	0.0021	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—ELMO1—esophageal cancer	0.00114	0.00275	CbGpPWpGaD
Baclofen—Myalgia—Capecitabine—esophageal cancer	0.00114	0.00207	CcSEcCtD
Baclofen—Chest pain—Capecitabine—esophageal cancer	0.00114	0.00207	CcSEcCtD
Baclofen—Anxiety—Capecitabine—esophageal cancer	0.00114	0.00206	CcSEcCtD
Baclofen—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.00113	0.00205	CcSEcCtD
Baclofen—Urinary tract disorder—Methotrexate—esophageal cancer	0.00113	0.00205	CcSEcCtD
Baclofen—Discomfort—Capecitabine—esophageal cancer	0.00113	0.00204	CcSEcCtD
Baclofen—Urethral disorder—Methotrexate—esophageal cancer	0.00112	0.00203	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—AKAP13—esophageal cancer	0.00112	0.00269	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—ADCYAP1—esophageal cancer	0.00112	0.00269	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—PDE4D—esophageal cancer	0.00112	0.00268	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.00112	0.00268	CbGpPWpGaD
Baclofen—Dry mouth—Capecitabine—esophageal cancer	0.00112	0.00202	CcSEcCtD
Baclofen—Visual impairment—Methotrexate—esophageal cancer	0.0011	0.002	CcSEcCtD
Baclofen—Confusional state—Capecitabine—esophageal cancer	0.0011	0.002	CcSEcCtD
Baclofen—Oedema—Capecitabine—esophageal cancer	0.00109	0.00198	CcSEcCtD
Baclofen—Infection—Capecitabine—esophageal cancer	0.00109	0.00197	CcSEcCtD
Baclofen—Shock—Capecitabine—esophageal cancer	0.00108	0.00195	CcSEcCtD
Baclofen—Nervous system disorder—Capecitabine—esophageal cancer	0.00107	0.00194	CcSEcCtD
Baclofen—Eye disorder—Methotrexate—esophageal cancer	0.00107	0.00194	CcSEcCtD
Baclofen—SLC22A8—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.00107	0.00257	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.00107	0.00257	CbGpPWpGaD
Baclofen—Tinnitus—Methotrexate—esophageal cancer	0.00107	0.00194	CcSEcCtD
Baclofen—Tachycardia—Capecitabine—esophageal cancer	0.00107	0.00193	CcSEcCtD
Baclofen—Asthenia—Cisplatin—esophageal cancer	0.00106	0.00193	CcSEcCtD
Baclofen—Cardiac disorder—Methotrexate—esophageal cancer	0.00106	0.00193	CcSEcCtD
Baclofen—Skin disorder—Capecitabine—esophageal cancer	0.00106	0.00192	CcSEcCtD
Baclofen—GABBR1—Signaling by GPCR—GNG7—esophageal cancer	0.00106	0.00255	CbGpPWpGaD
Baclofen—Hyperhidrosis—Capecitabine—esophageal cancer	0.00106	0.00192	CcSEcCtD
Baclofen—Anorexia—Capecitabine—esophageal cancer	0.00104	0.00189	CcSEcCtD
Baclofen—Angiopathy—Methotrexate—esophageal cancer	0.00104	0.00188	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—HIST1H2BM—esophageal cancer	0.00103	0.00248	CbGpPWpGaD
Baclofen—Mediastinal disorder—Methotrexate—esophageal cancer	0.00103	0.00187	CcSEcCtD
Baclofen—GABBR1—GPCR downstream signaling—CXCL2—esophageal cancer	0.00103	0.00248	CbGpPWpGaD
Baclofen—Chills—Methotrexate—esophageal cancer	0.00103	0.00186	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—PDE4D—esophageal cancer	0.00102	0.00246	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—WWOX—esophageal cancer	0.00102	0.00246	CbGpPWpGaD
Baclofen—Hypotension—Capecitabine—esophageal cancer	0.00102	0.00185	CcSEcCtD
Baclofen—Diarrhoea—Cisplatin—esophageal cancer	0.00101	0.00184	CcSEcCtD
Baclofen—Alopecia—Methotrexate—esophageal cancer	0.00101	0.00183	CcSEcCtD
Baclofen—Mental disorder—Methotrexate—esophageal cancer	0.001	0.00182	CcSEcCtD
Baclofen—Malnutrition—Methotrexate—esophageal cancer	0.000997	0.00181	CcSEcCtD
Baclofen—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000996	0.0018	CcSEcCtD
Baclofen—Insomnia—Capecitabine—esophageal cancer	0.000989	0.00179	CcSEcCtD
Baclofen—Paraesthesia—Capecitabine—esophageal cancer	0.000982	0.00178	CcSEcCtD
Baclofen—Dysgeusia—Methotrexate—esophageal cancer	0.000976	0.00177	CcSEcCtD
Baclofen—Dyspnoea—Capecitabine—esophageal cancer	0.000975	0.00177	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—GNG7—esophageal cancer	0.000973	0.00234	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—FKBP1A—esophageal cancer	0.000973	0.00234	CbGpPWpGaD
Baclofen—Back pain—Methotrexate—esophageal cancer	0.000964	0.00175	CcSEcCtD
Baclofen—Dyspepsia—Capecitabine—esophageal cancer	0.000962	0.00174	CcSEcCtD
Baclofen—GABBR1—GPCR downstream signaling—ANXA1—esophageal cancer	0.000958	0.0023	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—WIF1—esophageal cancer	0.000951	0.00229	CbGpPWpGaD
Baclofen—Decreased appetite—Capecitabine—esophageal cancer	0.00095	0.00172	CcSEcCtD
Baclofen—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000944	0.00171	CcSEcCtD
Baclofen—Vomiting—Cisplatin—esophageal cancer	0.000943	0.00171	CcSEcCtD
Baclofen—Fatigue—Capecitabine—esophageal cancer	0.000942	0.00171	CcSEcCtD
Baclofen—Vision blurred—Methotrexate—esophageal cancer	0.00094	0.0017	CcSEcCtD
Baclofen—GABBR1—Signaling by GPCR—CXCL2—esophageal cancer	0.000935	0.00225	CbGpPWpGaD
Baclofen—Rash—Cisplatin—esophageal cancer	0.000935	0.00169	CcSEcCtD
Baclofen—Constipation—Capecitabine—esophageal cancer	0.000935	0.00169	CcSEcCtD
Baclofen—Pain—Capecitabine—esophageal cancer	0.000935	0.00169	CcSEcCtD
Baclofen—Dermatitis—Cisplatin—esophageal cancer	0.000934	0.00169	CcSEcCtD
Baclofen—GABBR1—GPCR downstream signaling—SST—esophageal cancer	0.000932	0.00224	CbGpPWpGaD
Baclofen—Ill-defined disorder—Methotrexate—esophageal cancer	0.000925	0.00168	CcSEcCtD
Baclofen—Anaemia—Methotrexate—esophageal cancer	0.000922	0.00167	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—XIAP—esophageal cancer	0.000912	0.00219	CbGpPWpGaD
Baclofen—GABBR1—GPCR downstream signaling—GHRL—esophageal cancer	0.000908	0.00218	CbGpPWpGaD
Baclofen—Feeling abnormal—Capecitabine—esophageal cancer	0.000901	0.00163	CcSEcCtD
Baclofen—Malaise—Methotrexate—esophageal cancer	0.000899	0.00163	CcSEcCtD
Baclofen—Vertigo—Methotrexate—esophageal cancer	0.000896	0.00162	CcSEcCtD
Baclofen—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000894	0.00162	CcSEcCtD
Baclofen—Nausea—Cisplatin—esophageal cancer	0.000881	0.0016	CcSEcCtD
Baclofen—GABBR1—Signaling Pathways—CSNK1A1—esophageal cancer	0.000878	0.00211	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—ANXA1—esophageal cancer	0.00087	0.00209	CbGpPWpGaD
Baclofen—Urticaria—Capecitabine—esophageal cancer	0.000868	0.00157	CcSEcCtD
Baclofen—Abdominal pain—Capecitabine—esophageal cancer	0.000864	0.00157	CcSEcCtD
Baclofen—Body temperature increased—Capecitabine—esophageal cancer	0.000864	0.00157	CcSEcCtD
Baclofen—Convulsion—Methotrexate—esophageal cancer	0.000864	0.00157	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—CTNNA1—esophageal cancer	0.000862	0.00207	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—CXCL2—esophageal cancer	0.000857	0.00206	CbGpPWpGaD
Baclofen—Myalgia—Methotrexate—esophageal cancer	0.000849	0.00154	CcSEcCtD
Baclofen—Chest pain—Methotrexate—esophageal cancer	0.000849	0.00154	CcSEcCtD
Baclofen—GABBR1—Signaling by GPCR—SST—esophageal cancer	0.000846	0.00203	CbGpPWpGaD
Baclofen—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000843	0.00153	CcSEcCtD
Baclofen—Discomfort—Methotrexate—esophageal cancer	0.000839	0.00152	CcSEcCtD
Baclofen—GABBR1—Signaling by GPCR—GHRL—esophageal cancer	0.000824	0.00198	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—PFN1—esophageal cancer	0.000821	0.00197	CbGpPWpGaD
Baclofen—Confusional state—Methotrexate—esophageal cancer	0.00082	0.00149	CcSEcCtD
Baclofen—SLC22A8—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.00081	0.00195	CbGpPWpGaD
Baclofen—Infection—Methotrexate—esophageal cancer	0.000808	0.00147	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—PSME1—esophageal cancer	0.000801	0.00193	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—PSME2—esophageal cancer	0.000801	0.00193	CbGpPWpGaD
Baclofen—Nervous system disorder—Methotrexate—esophageal cancer	0.000798	0.00145	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—ANXA1—esophageal cancer	0.000797	0.00192	CbGpPWpGaD
Baclofen—Skin disorder—Methotrexate—esophageal cancer	0.00079	0.00143	CcSEcCtD
Baclofen—Hyperhidrosis—Methotrexate—esophageal cancer	0.000787	0.00143	CcSEcCtD
Baclofen—Asthenia—Capecitabine—esophageal cancer	0.000784	0.00142	CcSEcCtD
Baclofen—Anorexia—Methotrexate—esophageal cancer	0.000776	0.00141	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—SST—esophageal cancer	0.000775	0.00186	CbGpPWpGaD
Baclofen—Pruritus—Capecitabine—esophageal cancer	0.000773	0.0014	CcSEcCtD
Baclofen—Hypotension—Methotrexate—esophageal cancer	0.00076	0.00138	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—NOTCH3—esophageal cancer	0.000756	0.00182	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—GHRL—esophageal cancer	0.000756	0.00182	CbGpPWpGaD
Baclofen—Diarrhoea—Capecitabine—esophageal cancer	0.000748	0.00136	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—FBXW7—esophageal cancer	0.000743	0.00179	CbGpPWpGaD
Baclofen—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000741	0.00134	CcSEcCtD
Baclofen—GABBR1—Signaling Pathways—ELMO1—esophageal cancer	0.000738	0.00177	CbGpPWpGaD
Baclofen—Insomnia—Methotrexate—esophageal cancer	0.000736	0.00133	CcSEcCtD
Baclofen—SLC22A8—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.000735	0.00177	CbGpPWpGaD
Baclofen—Paraesthesia—Methotrexate—esophageal cancer	0.000731	0.00132	CcSEcCtD
Baclofen—Dyspnoea—Methotrexate—esophageal cancer	0.000725	0.00131	CcSEcCtD
Baclofen—Somnolence—Methotrexate—esophageal cancer	0.000723	0.00131	CcSEcCtD
Baclofen—Dizziness—Capecitabine—esophageal cancer	0.000723	0.00131	CcSEcCtD
Baclofen—GABBR1—Signaling Pathways—AKAP13—esophageal cancer	0.000721	0.00173	CbGpPWpGaD
Baclofen—Dyspepsia—Methotrexate—esophageal cancer	0.000716	0.0013	CcSEcCtD
Baclofen—Decreased appetite—Methotrexate—esophageal cancer	0.000707	0.00128	CcSEcCtD
Baclofen—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000702	0.00127	CcSEcCtD
Baclofen—Fatigue—Methotrexate—esophageal cancer	0.000702	0.00127	CcSEcCtD
Baclofen—Pain—Methotrexate—esophageal cancer	0.000696	0.00126	CcSEcCtD
Baclofen—Vomiting—Capecitabine—esophageal cancer	0.000695	0.00126	CcSEcCtD
Baclofen—Rash—Capecitabine—esophageal cancer	0.000689	0.00125	CcSEcCtD
Baclofen—Dermatitis—Capecitabine—esophageal cancer	0.000689	0.00125	CcSEcCtD
Baclofen—Headache—Capecitabine—esophageal cancer	0.000685	0.00124	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—NOTCH2—esophageal cancer	0.000678	0.00163	CbGpPWpGaD
Baclofen—Feeling abnormal—Methotrexate—esophageal cancer	0.000671	0.00122	CcSEcCtD
Baclofen—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000665	0.00121	CcSEcCtD
Baclofen—GABBR1—Signaling Pathways—HIST1H2BM—esophageal cancer	0.000665	0.0016	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—PDE4D—esophageal cancer	0.000659	0.00158	CbGpPWpGaD
Baclofen—Nausea—Capecitabine—esophageal cancer	0.000649	0.00118	CcSEcCtD
Baclofen—Urticaria—Methotrexate—esophageal cancer	0.000646	0.00117	CcSEcCtD
Baclofen—Abdominal pain—Methotrexate—esophageal cancer	0.000643	0.00117	CcSEcCtD
Baclofen—Body temperature increased—Methotrexate—esophageal cancer	0.000643	0.00117	CcSEcCtD
Baclofen—GABBR1—Signaling Pathways—GNG7—esophageal cancer	0.000627	0.00151	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—TGFBR2—esophageal cancer	0.000601	0.00145	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—XIAP—esophageal cancer	0.000588	0.00141	CbGpPWpGaD
Baclofen—Asthenia—Methotrexate—esophageal cancer	0.000584	0.00106	CcSEcCtD
Baclofen—Pruritus—Methotrexate—esophageal cancer	0.000576	0.00104	CcSEcCtD
Baclofen—GABBR2—Signaling Pathways—SMAD4—esophageal cancer	0.000569	0.00137	CbGpPWpGaD
Baclofen—Diarrhoea—Methotrexate—esophageal cancer	0.000557	0.00101	CcSEcCtD
Baclofen—GABBR1—Signaling Pathways—CTNNA1—esophageal cancer	0.000556	0.00134	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—CXCL2—esophageal cancer	0.000553	0.00133	CbGpPWpGaD
Baclofen—Dizziness—Methotrexate—esophageal cancer	0.000538	0.000975	CcSEcCtD
Baclofen—Vomiting—Methotrexate—esophageal cancer	0.000517	0.000938	CcSEcCtD
Baclofen—GABBR1—Signaling Pathways—PSME2—esophageal cancer	0.000516	0.00124	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—PSME1—esophageal cancer	0.000516	0.00124	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—ANXA1—esophageal cancer	0.000514	0.00123	CbGpPWpGaD
Baclofen—Rash—Methotrexate—esophageal cancer	0.000513	0.00093	CcSEcCtD
Baclofen—Dermatitis—Methotrexate—esophageal cancer	0.000513	0.000929	CcSEcCtD
Baclofen—Headache—Methotrexate—esophageal cancer	0.00051	0.000924	CcSEcCtD
Baclofen—GABBR1—Signaling Pathways—SST—esophageal cancer	0.0005	0.0012	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—NOTCH3—esophageal cancer	0.000487	0.00117	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—GHRL—esophageal cancer	0.000487	0.00117	CbGpPWpGaD
Baclofen—Nausea—Methotrexate—esophageal cancer	0.000483	0.000876	CcSEcCtD
Baclofen—GABBR1—Signaling Pathways—FBXW7—esophageal cancer	0.000479	0.00115	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—HIF1A—esophageal cancer	0.000466	0.00112	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000448	0.00108	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—KDR—esophageal cancer	0.000445	0.00107	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—NOTCH2—esophageal cancer	0.000437	0.00105	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.00043	0.00103	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—NOTCH1—esophageal cancer	0.00042	0.00101	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—TGFBR2—esophageal cancer	0.000387	0.000931	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—CREBBP—esophageal cancer	0.00038	0.000914	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—EGFR—esophageal cancer	0.000374	0.000898	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—SMAD4—esophageal cancer	0.000367	0.000881	CbGpPWpGaD
Baclofen—GABBR2—GPCR downstream signaling—PIK3CA—esophageal cancer	0.000357	0.000859	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—NOS3—esophageal cancer	0.000341	0.000819	CbGpPWpGaD
Baclofen—GABBR2—Signaling by GPCR—PIK3CA—esophageal cancer	0.000324	0.00078	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—ERBB2—esophageal cancer	0.000319	0.000766	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—HIF1A—esophageal cancer	0.0003	0.000721	CbGpPWpGaD
Baclofen—SLC22A8—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000287	0.000691	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—KDR—esophageal cancer	0.000287	0.00069	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—CCND1—esophageal cancer	0.000281	0.000676	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—CDKN1A—esophageal cancer	0.000272	0.000654	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—NOTCH1—esophageal cancer	0.00027	0.00065	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—EP300—esophageal cancer	0.000259	0.000623	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—CREBBP—esophageal cancer	0.000245	0.000589	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—EGFR—esophageal cancer	0.000241	0.000579	CbGpPWpGaD
Baclofen—GABBR1—GPCR downstream signaling—PIK3CA—esophageal cancer	0.00023	0.000553	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—MYC—esophageal cancer	0.000226	0.000543	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—EGFR—esophageal cancer	0.000221	0.000531	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—NOS3—esophageal cancer	0.000219	0.000527	CbGpPWpGaD
Baclofen—GABBR1—Signaling by GPCR—PIK3CA—esophageal cancer	0.000209	0.000502	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—ERBB2—esophageal cancer	0.000205	0.000493	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—PIK3CA—esophageal cancer	0.000192	0.000461	CbGpPWpGaD
Baclofen—GABBR2—Signaling Pathways—TP53—esophageal cancer	0.000185	0.000446	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—CCND1—esophageal cancer	0.000181	0.000436	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—CDKN1A—esophageal cancer	0.000175	0.000422	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—EP300—esophageal cancer	0.000167	0.000401	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—MYC—esophageal cancer	0.000145	0.00035	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—EGFR—esophageal cancer	0.000142	0.000342	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—PIK3CA—esophageal cancer	0.000123	0.000297	CbGpPWpGaD
Baclofen—GABBR1—Signaling Pathways—TP53—esophageal cancer	0.000119	0.000287	CbGpPWpGaD
